{
    "id": "dbpedia_625_3",
    "rank": 32,
    "data": {
        "url": "https://www.revisor.mn.gov/statutes/cite/152/full",
        "read_more_link": "",
        "language": "en",
        "title": "Ch. 152 MN Statutes",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://www.revisor.mn.gov/static/images/capitol2.bfdc60e0b266.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "§\n\nSubd. 2.Schedule I.\n\n(a) Schedule I consists of the substances listed in this subdivision.\n\n(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the following substances, including their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers, and salts is possible:\n\n(1) acetylmethadol;\n\n(2) allylprodine;\n\n(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl acetate);\n\n(4) alphameprodine;\n\n(5) alphamethadol;\n\n(6) alpha-methylfentanyl benzethidine;\n\n(7) betacetylmethadol;\n\n(8) betameprodine;\n\n(9) betamethadol;\n\n(10) betaprodine;\n\n(11) clonitazene;\n\n(12) dextromoramide;\n\n(13) diampromide;\n\n(14) diethyliambutene;\n\n(15) difenoxin;\n\n(16) dimenoxadol;\n\n(17) dimepheptanol;\n\n(18) dimethyliambutene;\n\n(19) dioxaphetyl butyrate;\n\n(20) dipipanone;\n\n(21) ethylmethylthiambutene;\n\n(22) etonitazene;\n\n(23) etoxeridine;\n\n(24) furethidine;\n\n(25) hydroxypethidine;\n\n(26) ketobemidone;\n\n(27) levomoramide;\n\n(28) levophenacylmorphan;\n\n(29) 3-methylfentanyl;\n\n(30) acetyl-alpha-methylfentanyl;\n\n(31) alpha-methylthiofentanyl;\n\n(32) benzylfentanyl beta-hydroxyfentanyl;\n\n(33) beta-hydroxy-3-methylfentanyl;\n\n(34) 3-methylthiofentanyl;\n\n(35) thenylfentanyl;\n\n(36) thiofentanyl;\n\n(37) para-fluorofentanyl;\n\n(38) morpheridine;\n\n(39) 1-methyl-4-phenyl-4-propionoxypiperidine;\n\n(40) noracymethadol;\n\n(41) norlevorphanol;\n\n(42) normethadone;\n\n(43) norpipanone;\n\n(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);\n\n(45) phenadoxone;\n\n(46) phenampromide;\n\n(47) phenomorphan;\n\n(48) phenoperidine;\n\n(49) piritramide;\n\n(50) proheptazine;\n\n(51) properidine;\n\n(52) propiram;\n\n(53) racemoramide;\n\n(54) tilidine;\n\n(55) trimeperidine;\n\n(56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);\n\n(57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-\n\nmethylbenzamide(U47700);\n\n(58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl);\n\n(59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol);\n\n(60) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropryl fentanyl);\n\n(61) N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide) (butyryl fentanyl);\n\n(62) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) (MT-45);\n\n(63) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopentyl fentanyl);\n\n(64) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);\n\n(65) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide (valeryl fentanyl);\n\n(66) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (para-chloroisobutyryl fentanyl);\n\n(67) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-fluorobutyryl fentanyl);\n\n(68) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-methoxybutyryl fentanyl);\n\n(69) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil);\n\n(70) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyryl fentanyl or para-fluoroisobutyryl fentanyl);\n\n(71) N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl or acryloylfentanyl);\n\n(72) 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl fentanyl);\n\n(73) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-fluorofentanyl or 2-fluorofentanyl);\n\n(74) N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide (tetrahydrofuranyl fentanyl);\n\n(75) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers, meaning any substance not otherwise listed under another federal Administration Controlled Substance Code Number or not otherwise listed in this section, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act, United States Code, title 21, section 355, that is structurally related to fentanyl by one or more of the following modifications:\n\n(i) replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;\n\n(ii) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;\n\n(iii) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups;\n\n(iv) replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; or\n\n(v) replacement of the N-propionyl group by another acyl group;\n\n(76) 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3- dihydro-2H-benzo[d]imidazol-2-one (brorphine);\n\n(77) 4'-methyl acetyl fentanyl;\n\n(78) beta-hydroxythiofentanyl;\n\n(79) beta-methyl fentanyl;\n\n(80) beta'-phenyl fentanyl;\n\n(81) crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide);\n\n(82) cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);\n\n(83) fentanyl carbamate;\n\n(84) isotonitazene (N,N-diethyl-2-(2-(4 isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);\n\n(85) para-fluoro furanyl fentanyl;\n\n(86) para-methylfentanyl;\n\n(87) phenyl fentanyl;\n\n(88) ortho-fluoroacryl fentanyl;\n\n(89) ortho-fluorobutyryl fentanyl;\n\n(90) ortho-fluoroisobutyryl fentanyl;\n\n(91) ortho-methyl acetylfentanyl;\n\n(92) thiofuranyl fentanyl;\n\n(93) metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);\n\n(94) metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);\n\n(95) etodesnitazene; etazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine);\n\n(96) protonitazene (N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);\n\n(97) butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine);\n\n(98) flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine); and\n\n(99) N-pyrrolidino etonitazene; etonitazepyne (2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole).\n\n(c) Opium derivatives. Any of the following substances, their analogs, salts, isomers, and salts of isomers, unless specifically excepted or unless listed in another schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:\n\n(1) acetorphine;\n\n(2) acetyldihydrocodeine;\n\n(3) benzylmorphine;\n\n(4) codeine methylbromide;\n\n(5) codeine-n-oxide;\n\n(6) cyprenorphine;\n\n(7) desomorphine;\n\n(8) dihydromorphine;\n\n(9) drotebanol;\n\n(10) etorphine;\n\n(11) heroin;\n\n(12) hydromorphinol;\n\n(13) methyldesorphine;\n\n(14) methyldihydromorphine;\n\n(15) morphine methylbromide;\n\n(16) morphine methylsulfonate;\n\n(17) morphine-n-oxide;\n\n(18) myrophine;\n\n(19) nicocodeine;\n\n(20) nicomorphine;\n\n(21) normorphine;\n\n(22) pholcodine; and\n\n(23) thebacon.\n\n(d) Hallucinogens. Any material, compound, mixture or preparation which contains any quantity of the following substances, their analogs, salts, isomers (whether optical, positional, or geometric), and salts of isomers, unless specifically excepted or unless listed in another schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:\n\n(1) methylenedioxy amphetamine;\n\n(2) methylenedioxymethamphetamine;\n\n(3) methylenedioxy-N-ethylamphetamine (MDEA);\n\n(4) n-hydroxy-methylenedioxyamphetamine;\n\n(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);\n\n(6) 2,5-dimethoxyamphetamine (2,5-DMA);\n\n(7) 4-methoxyamphetamine;\n\n(8) 5-methoxy-3, 4-methylenedioxyamphetamine;\n\n(9) alpha-ethyltryptamine;\n\n(10) bufotenine;\n\n(11) diethyltryptamine;\n\n(12) dimethyltryptamine;\n\n(13) 3,4,5-trimethoxyamphetamine;\n\n(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);\n\n(15) ibogaine;\n\n(16) lysergic acid diethylamide (LSD);\n\n(17) mescaline;\n\n(18) parahexyl;\n\n(19) N-ethyl-3-piperidyl benzilate;\n\n(20) N-methyl-3-piperidyl benzilate;\n\n(21) psilocybin;\n\n(22) psilocyn;\n\n(23) tenocyclidine (TPCP or TCP);\n\n(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);\n\n(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);\n\n(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);\n\n(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);\n\n(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);\n\n(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);\n\n(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);\n\n(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);\n\n(32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);\n\n(33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);\n\n(34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);\n\n(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);\n\n(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);\n\n(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);\n\n(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine (2-CB-FLY);\n\n(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);\n\n(40) alpha-methyltryptamine (AMT);\n\n(41) N,N-diisopropyltryptamine (DiPT);\n\n(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);\n\n(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);\n\n(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);\n\n(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);\n\n(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);\n\n(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);\n\n(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);\n\n(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);\n\n(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);\n\n(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);\n\n(52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);\n\n(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);\n\n(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);\n\n(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);\n\n(56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);\n\n(57) methoxetamine (MXE);\n\n(58) 5-iodo-2-aminoindane (5-IAI);\n\n(59) 5,6-methylenedioxy-2-aminoindane (MDAI);\n\n(60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);\n\n(61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);\n\n(62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);\n\n(63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);\n\n(64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);\n\n(65) N,N-Dipropyltryptamine (DPT);\n\n(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);\n\n(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);\n\n(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);\n\n(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);\n\n(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine, ethketamine, NENK);\n\n(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);\n\n(72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and\n\n(73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).\n\n(e) Peyote. All parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant, and every compound, manufacture, salts, derivative, mixture, or preparation of the plant, its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian Church, and members of the American Indian Church are exempt from registration. Any person who manufactures peyote for or distributes peyote to the American Indian Church, however, is required to obtain federal registration annually and to comply with all other requirements of law.\n\n(f) Central nervous system depressants. Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:\n\n(1) mecloqualone;\n\n(2) methaqualone;\n\n(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;\n\n(4) flunitrazepam;\n\n(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine, methoxyketamine);\n\n(6) tianeptine;\n\n(7) clonazolam;\n\n(8) etizolam;\n\n(9) flubromazolam; and\n\n(10) flubromazepam.\n\n(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:\n\n(1) aminorex;\n\n(2) cathinone;\n\n(3) fenethylline;\n\n(4) methcathinone;\n\n(5) methylaminorex;\n\n(6) N,N-dimethylamphetamine;\n\n(7) N-benzylpiperazine (BZP);\n\n(8) methylmethcathinone (mephedrone);\n\n(9) 3,4-methylenedioxy-N-methylcathinone (methylone);\n\n(10) methoxymethcathinone (methedrone);\n\n(11) methylenedioxypyrovalerone (MDPV);\n\n(12) 3-fluoro-N-methylcathinone (3-FMC);\n\n(13) methylethcathinone (MEC);\n\n(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);\n\n(15) dimethylmethcathinone (DMMC);\n\n(16) fluoroamphetamine;\n\n(17) fluoromethamphetamine;\n\n(18) α-methylaminobutyrophenone (MABP or buphedrone);\n\n(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);\n\n(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);\n\n(21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or naphyrone);\n\n(22) (alpha-pyrrolidinopentiophenone (alpha-PVP);\n\n(23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);\n\n(24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);\n\n(25) 4-methyl-N-ethylcathinone (4-MEC);\n\n(26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);\n\n(27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);\n\n(28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);\n\n(29) 4-fluoro-N-methylcathinone (4-FMC);\n\n(30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);\n\n(31) alpha-pyrrolidinobutiophenone (α-PBP);\n\n(32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);\n\n(33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);\n\n(34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);\n\n(35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);\n\n(36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);\n\n(37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);\n\n(38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP);\n\n(39) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one (N-ethylpentylone, ephylone);\n\n(40) any other substance, except bupropion or compounds listed under a different schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways:\n\n(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;\n\n(ii) by substitution at the 3-position with an acyclic alkyl substituent;\n\n(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups; or\n\n(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure;\n\n(41) 4,4'-dimethylaminorex (4,4'-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine);\n\n(42) 4-chloro-alpha-pyrrolidinovalerophenone (4-chloro-A-PVP);\n\n(43) para-methoxymethamphetamine (PMMA), 1-(4-methoxyphenyl)-N-methylpropan-2-amine; and\n\n(44) N-ethylhexedrone.\n\n(h) Synthetic cannabinoids, including the following substances:\n\n(1) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of naphthoylindoles include, but are not limited to:\n\n(i) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);\n\n(ii) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);\n\n(iii) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);\n\n(iv) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);\n\n(v) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);\n\n(vi) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);\n\n(vii) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);\n\n(viii) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);\n\n(ix) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);\n\n(x) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).\n\n(2) Napthylmethylindoles, which are any compounds containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:\n\n(i) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);\n\n(ii) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).\n\n(3) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to, (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).\n\n(4) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of naphthylemethylindenes include, but are not limited to, E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).\n\n(5) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent. Examples of phenylacetylindoles include, but are not limited to:\n\n(i) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);\n\n(ii) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);\n\n(iii) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);\n\n(iv) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).\n\n(6) Cyclohexylphenols, which are compounds containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not limited to:\n\n(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);\n\n(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (Cannabicyclohexanol or CP 47,497 C8 homologue);\n\n(iii) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl] -phenol (CP 55,940).\n\n(7) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of benzoylindoles include, but are not limited to:\n\n(i) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);\n\n(ii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);\n\n(iii) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN 48,098 or Pravadoline).\n\n(8) Others specifically named:\n\n(i) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);\n\n(ii) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);\n\n(iii) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de] -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);\n\n(iv) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);\n\n(v) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (XLR-11);\n\n(vi) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide (AKB-48(APINACA));\n\n(vii) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5-Fluoro-AKB-48);\n\n(viii) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);\n\n(ix) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro PB-22);\n\n(x) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole- 3-carboxamide (AB-PINACA);\n\n(xi) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]- 1H-indazole-3-carboxamide (AB-FUBINACA);\n\n(xii) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H- indazole-3-carboxamide(AB-CHMINACA);\n\n(xiii) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3- methylbutanoate (5-fluoro-AMB);\n\n(xiv) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);\n\n(xv) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone) (FUBIMINA);\n\n(xvi) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);\n\n(xvii) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl) -1H-indole-3-carboxamide (5-fluoro-ABICA);\n\n(xviii) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) -1H-indole-3-carboxamide;\n\n(xix) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) -1H-indazole-3-carboxamide;\n\n(xx) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-dimethylbutanoate;\n\n(xxi) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl) -1H-indazole-3-carboxamide (MAB-CHMINACA);\n\n(xxii) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA);\n\n(xxiii) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);\n\n(xxiv) N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-\n\n3-carboxamide. (APP-CHMINACA);\n\n(xxv) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and\n\n(xxvi) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).\n\n(9) Additional substances specifically named:\n\n(i) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl) -1H-pyrrolo[2,3-B]pyridine-3-carboxamide (5F-CUMYL-P7AICA);\n\n(ii) 1-(4-cyanobutyl)-N-(2- phenylpropan-2-yl)-1 H-indazole-3-carboxamide (4-CN-Cumyl-Butinaca);\n\n(iii) naphthalen-1-yl-1-(5-fluoropentyl)-1-H-indole-3-carboxylate (NM2201; CBL2201);\n\n(iv) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl) -1H-indazole-3-carboxamide (5F-ABPINACA);\n\n(v) methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB CHMICA);\n\n(vi) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (5F-ADB; 5F-MDMB-PINACA);\n\n(vii) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl) 1H-indazole-3-carboxamide (ADB-FUBINACA);\n\n(viii) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide;\n\n(ix) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;\n\n(x) methyl 2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3,3-dimethylbutanoate;\n\n(xi) methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;\n\n(xii) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate;\n\n(xiii) methyl 2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3- methylbutanoate;\n\n(xiv) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide; and\n\n(xv) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide.\n\n(i) A controlled substance analog, to the extent that it is implicitly or explicitly intended for human consumption.\n\n§\n\nSubd. 4.Schedule III.\n\n(a) Schedule III consists of the substances listed in this subdivision.\n\n(b) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:\n\n(1) benzphetamine;\n\n(2) chlorphentermine;\n\n(3) clortermine;\n\n(4) phendimetrazine.\n\n(c) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:\n\n(1) any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule;\n\n(2) any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs and approved by the food and drug administration for marketing only as a suppository;\n\n(3) any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules;\n\n(4) any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal Food, Drug, and Cosmetic Act;\n\n(5) any of the following substances:\n\n(i) chlorhexadol;\n\n(ii) ketamine, its salts, isomers and salts of isomers;\n\n(iii) lysergic acid;\n\n(iv) lysergic acid amide;\n\n(v) methyprylon;\n\n(vi) sulfondiethylmethane;\n\n(vii) sulfonenthylmethane;\n\n(viii) sulfonmethane;\n\n(ix) tiletamine and zolazepam and any salt thereof;\n\n(x) embutramide;\n\n(xi) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-Dihydropyridin-3-yl) benzonitrile].\n\n(d) Nalorphine.\n\n(e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as follows:\n\n(1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;\n\n(2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;\n\n(3) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;\n\n(4) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;\n\n(5) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;\n\n(6) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.\n\n(f) Anabolic steroids, human growth hormone, and chorionic gonadotropin.\n\n(1) Anabolic steroids, for purposes of this subdivision, means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone, and includes:\n\n(i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;\n\n(ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;\n\n(iii) androstanedione (5[alpha]-androstan-3,17-dione);\n\n(iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-l-ene;\n\n(v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);\n\n(vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);\n\n(vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);\n\n(viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);\n\n(ix) 4-androstenedione (androst-4-en-3,17-dione);\n\n(x) 5-androstenedione (androst-5-en-3,17-dione);\n\n(xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);\n\n(xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);\n\n(xiii) boldione (androsta-1,4-diene-3,17-dione);\n\n(xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);\n\n(xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);\n\n(xvi) dehydrochloromethyltestosterone (4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one);\n\n(xvii) desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol);\n\n(xviii) [delta]1-dihydrotestosterone- (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);\n\n(xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one);\n\n(xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one);\n\n(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);\n\n(xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one);\n\n(xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one);\n\n(xxiv) furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta] -hydroxygon-4-en-3-one;\n\n(xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one);\n\n(xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);\n\n(xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);\n\n(xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);\n\n(xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one);\n\n(xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene);\n\n(xxxi) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-androstan-17beta-ol-3-one);\n\n(xxxii) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);\n\n(xxxiii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane;\n\n(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;\n\n(xxxv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene;\n\n(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);\n\n(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);\n\n(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);\n\n(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one);\n\n(xl) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);\n\n(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone (17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one);\n\n(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one);\n\n(xliii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene;\n\n(xliv) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol (3[beta],17[beta]-dihydroxyestr-5-ene;\n\n(xlv) 3[alpha],17[beta]-dihydroxyestr-5-ene);\n\n(xlvi) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);\n\n(xlvii) 19-nor-5-androstenedione (estr-5-en-3,17-dione);\n\n(xlviii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);\n\n(xlix) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);\n\n(l) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);\n\n(li) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);\n\n(lii) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one);\n\n(liii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one);\n\n(liv) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one);\n\n(lv) prostanozol (17 beta-hydroxy-5 alpha-androstano[3,2-C]pryazole;\n\n(lvi) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole);\n\n(lvii) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one);\n\n(lviii) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);\n\n(lix) testosterone (17[beta]-hydroxyandrost-4-en-3-one);\n\n(lx) tetrahydrogestrinone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);\n\n(lxi) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one);\n\n(lxii) any salt, ester, or ether of a drug or substance described in this paragraph.\n\nAnabolic steroids are not included if they are: (A) expressly intended for administration through implants to cattle or other nonhuman species; and (B) approved by the United States Food and Drug Administration for that use;\n\n(2) Human growth hormones.\n\n(3) Chorionic gonadotropin, except that a product containing chorionic gonadotropin is not included if it is:\n\n(i) expressly intended for administration to cattle or other nonhuman species; and\n\n(ii) approved by the United States Food and Drug Administration for that use.\n\n(g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved product.\n\n(h) Any material, compound, mixture, or preparation containing the following narcotic drug or its salt: buprenorphine.\n\n(i) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically excepted or unless listed in another schedule, any natural or synthetic material, compound, mixture, or preparation that contains any quantity of the following substances, their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the isomers, esters, ethers, or salts is possible:\n\n(1) marijuana;\n\n(2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, except that tetrahydrocannabinols do not include any material, compound, mixture, or preparation that qualifies as industrial hemp as defined in section 18K.02, subdivision 3; synthetic equivalents of the substances contained in the cannabis plant or in the resinous extractives of the plant; or synthetic substances with similar chemical structure and pharmacological activity to those substances contained in the plant or resinous extract, including but not limited to 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol.\n\n§\n\nSubd. 6.Schedule V; restrictions on methamphetamine precursor drugs.\n\n(a) As used in this subdivision, the following terms have the meanings given:\n\n(1) \"methamphetamine precursor drug\" means any compound, mixture, or preparation intended for human consumption containing ephedrine or pseudoephedrine as its sole active ingredient or as one of its active ingredients; and\n\n(2) \"over-the-counter sale\" means a retail sale of a drug or product but does not include the sale of a drug or product pursuant to the terms of a valid prescription.\n\n(b) The following items are listed in Schedule V:\n\n(1) any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:\n\n(i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;\n\n(ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;\n\n(iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;\n\n(iv) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; or\n\n(v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.\n\n(2) Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substance having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: pyrovalerone.\n\n(3) Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substance having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers:\n\n(i) ezogabine;\n\n(ii) pregabalin;\n\n(iii) lacosamide;\n\n(iv) cenobamate [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl]carbamate.\n\n(4) Any compound, mixture, or preparation containing ephedrine or pseudoephedrine as its sole active ingredient or as one of its active ingredients.\n\n(c) No person may sell in a single over-the-counter sale more than two packages of a methamphetamine precursor drug or a combination of methamphetamine precursor drugs or any combination of packages exceeding a total weight of six grams, calculated as the base.\n\n(d) Over-the-counter sales of methamphetamine precursor drugs are limited to:\n\n(1) packages containing not more than a total of three grams of one or more methamphetamine precursor drugs, calculated in terms of ephedrine base or pseudoephedrine base; or\n\n(2) for nonliquid products, sales in blister packs, where each blister contains not more than two dosage units, or, if the use of blister packs is not technically feasible, sales in unit dose packets or pouches.\n\n(e) A business establishment that offers for sale methamphetamine precursor drugs in an over-the-counter sale shall ensure that all packages of the drugs are displayed behind a checkout counter where the public is not permitted and are offered for sale only by a licensed pharmacist, a registered pharmacy technician, or a pharmacy clerk. The establishment shall ensure that the person making the sale requires the buyer:\n\n(1) to provide photographic identification showing the buyer's date of birth; and\n\n(2) to sign a written or electronic document detailing the date of the sale, the name of the buyer, and the amount of the drug sold.\n\nA document described under clause (2) must be retained by the establishment for at least three years and must at all reasonable times be open to the inspection of any law enforcement agency.\n\nNothing in this paragraph requires the buyer to obtain a prescription for the drug's purchase.\n\n(f) No person may acquire through over-the-counter sales more than six grams of methamphetamine precursor drugs, calculated as the base, within a 30-day period.\n\n(g) No person may sell in an over-the-counter sale a methamphetamine precursor drug to a person under the age of 18 years. It is an affirmative defense to a charge under this paragraph if the defendant proves by a preponderance of the evidence that the defendant reasonably and in good faith relied on proof of age as described in section 340A.503, subdivision 6.\n\n(h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of a misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to payment of a fine of not more than $1,000, or both.\n\n(i) An owner, operator, supervisor, or manager of a business establishment that offers for sale methamphetamine precursor drugs whose employee or agent is convicted of or charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal penalties for violating any of those paragraphs if the person:\n\n(1) did not have prior knowledge of, participate in, or direct the employee or agent to commit the violation; and\n\n(2) documents that an employee training program was in place to provide the employee or agent with information on the state and federal laws and regulations regarding methamphetamine precursor drugs.\n\n(j) Any person employed by a business establishment that offers for sale methamphetamine precursor drugs who sells such a drug to any person in a suspicious transaction shall report the transaction to the owner, supervisor, or manager of the establishment. The owner, supervisor, or manager may report the transaction to local law enforcement. A person who reports information under this subdivision in good faith is immune from civil liability relating to the report.\n\n(k) Paragraphs (b) to (j) do not apply to:\n\n(1) pediatric products labeled pursuant to federal regulation primarily intended for administration to children under 12 years of age according to label instructions;\n\n(2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as being manufactured in a manner that prevents the drug from being used to manufacture methamphetamine;\n\n(3) methamphetamine precursor drugs in gel capsule or liquid form; or\n\n(4) compounds, mixtures, or preparations in powder form where pseudoephedrine constitutes less than one percent of its total weight and is not its sole active ingredient.\n\n(l) The Board of Pharmacy, in consultation with the Department of Public Safety, shall certify methamphetamine precursor drugs that meet the requirements of paragraph (k), clause (2), and publish an annual listing of these drugs.\n\n(m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy pursuant to sections 151.43 to 151.471 and registered with and regulated by the United States Drug Enforcement Administration are exempt from the methamphetamine precursor drug storage requirements of this section.\n\n(n) This section preempts all local ordinances or regulations governing the sale by a business establishment of over-the-counter products containing ephedrine or pseudoephedrine. All ordinances enacted prior to the effective date of this act are void.\n\n§\n\nSubd. 2.Property-related prohibitions; notice; website.\n\n(a) As used in this subdivision:\n\n(1) \"clandestine lab site\" has the meaning given in subdivision 1, paragraph (a);\n\n(2) \"property\" means publicly or privately owned real property including buildings and other structures, motor vehicles as defined in section 609.487, subdivision 2a, public waters, and public rights-of-way;\n\n(3) \"remediation\" has the meaning given in subdivision 1, paragraph (a); and\n\n(4) \"removal\" has the meaning given in subdivision 1, paragraph (a).\n\n(b) A peace officer who arrests a person at a clandestine lab site shall notify the appropriate county or local health department, state duty officer, and child protection services of the arrest and the location of the site.\n\n(c) A county or local health department or sheriff shall order that any property or portion of a property that has been found to be a clandestine lab site and contaminated by substances, chemicals, or items of any kind used in the manufacture of methamphetamine or any part of the manufacturing process, or the by-products or degradates of manufacturing methamphetamine be prohibited from being occupied or used until it has been assessed and remediated as provided in the Department of Health's clandestine drug labs general cleanup guidelines. The remediation shall be accomplished by a contractor who will make the verification required under paragraph (e).\n\n(d) Unless clearly inapplicable, the procedures specified in chapter 145A and any related rules adopted under that chapter addressing the enforcement of public health laws, the removal and abatement of public health nuisances, and the remedies available to property owners or occupants apply to this subdivision.\n\n(e) Upon the proper removal and remediation of any property used as a clandestine lab site, the contractor shall verify to the property owner and the applicable authority that issued the order under paragraph (c) that the work was completed according to the Department of Health's clandestine drug labs general cleanup guidelines and best practices. The contractor shall provide the verification to the property owner and the applicable authority within five days from the completion of the remediation. Following this, the applicable authority shall vacate its order.\n\n(f) If a contractor issues a verification and the property was not remediated according to the Department of Health's clandestine drug labs general cleanup guidelines, the contractor is liable to the property owner for the additional costs relating to the proper remediation of the property according to the guidelines and for reasonable attorney fees for collection of costs by the property owner. An action under this paragraph must be commenced within six years from the date on which the verification was issued by the contractor.\n\n(g) If the applicable authority determines under paragraph (c) that a motor vehicle has been contaminated by substances, chemicals, or items of any kind used in the manufacture of methamphetamine or any part of the manufacturing process, or the by-products or degradates of manufacturing methamphetamine and if the authority is able to obtain the certificate of title for the motor vehicle, the authority shall notify the registrar of motor vehicles of this fact and in addition, forward the certificate of title to the registrar. The authority shall also notify the registrar when it vacates its order under paragraph (e).\n\n(h) The applicable authority issuing an order under paragraph (c) shall record with the county recorder or registrar of titles of the county where the clandestine lab is located an affidavit containing the name of the owner, a legal description of the property where the clandestine lab was located, and a map drawn from available information showing the boundary of the property and the location of the contaminated area on the property that is prohibited from being occupied or used that discloses to any potential transferee:\n\n(1) that the property, or portion of the property, was the site of a clandestine lab;\n\n(2) the location, condition, and circumstances of the clandestine lab, to the full extent known or reasonably ascertainable; and\n\n(3) that the use of the property or some portion of it may be restricted as provided by paragraph (c).\n\nIf an inaccurate drawing or description is filed, the authority, on request of the owner or another interested person, shall file a supplemental affidavit with a corrected drawing or description.\n\nIf the authority vacates its order under paragraph (e), the authority shall record an affidavit that contains the recording information of the above affidavit and states that the order is vacated. Upon filing the affidavit vacating the order, the affidavit and the affidavit filed under this paragraph, together with the information set forth in the affidavits, cease to constitute either actual or constructive notice.\n\n(i) If proper removal and remediation has occurred on the property, an interested party may record an affidavit indicating that this has occurred. Upon filing the affidavit described in this paragraph, the affidavit and the affidavit filed under paragraph (h), together with the information set forth in the affidavits, cease to constitute either actual or constructive notice. Failure to record an affidavit under this section does not affect or prevent any transfer of ownership of the property.\n\n(j) The county recorder or registrar of titles must record all affidavits presented under paragraph (h) or (i) in a manner that ensures their disclosure in the ordinary course of a title search of the subject property.\n\n(k) The commissioner of health shall post on the Internet contact information for each local community health services administrator.\n\n(l) Each local community health services administrator shall maintain information related to property within the administrator's jurisdiction that is currently or was previously subject to an order issued under paragraph (c). The information maintained must include the name of the owner, the location of the property, the extent of the contamination, the status of the removal and remediation work on the property, and whether the order has been vacated. The administrator shall make this information available to the public either upon request or by other means.\n\n(m) Before signing an agreement to sell or transfer real property, the seller or transferor must disclose in writing to the buyer or transferee if, to the seller's or transferor's knowledge, methamphetamine production has occurred on the property. If methamphetamine production has occurred on the property, the disclosure shall include a statement to the buyer or transferee informing the buyer or transferee:\n\n(1) whether an order has been issued on the property as described in paragraph (c);\n\n(2) whether any orders issued against the property under paragraph (c) have been vacated under paragraph (j); or\n\n(3) if there was no order issued against the property and the seller or transferor is aware that methamphetamine production has occurred on the property, the status of removal and remediation on the property.\n\n(n) Unless the buyer or transferee and seller or transferor agree to the contrary in writing before the closing of the sale, a seller or transferor who fails to disclose, to the best of their knowledge, at the time of sale any of the facts required, and who knew or had reason to know of methamphetamine production on the property, is liable to the buyer or transferee for:\n\n(1) costs relating to remediation of the property according to the Department of Health's clandestine drug labs general cleanup guidelines and best practices; and\n\n(2) reasonable attorney fees for collection of costs from the seller or transferor.\n\nAn action under this paragraph must be commenced within six years after the date on which the buyer or transferee closed the purchase or transfer of the real property where the methamphetamine production occurred.\n\n(o) This section preempts all local ordinances relating to the sale or transfer of real property designated as a clandestine lab site.\n\n§\n\nSubd. 6.Access to reporting system data.\n\n(a) Except as indicated in this subdivision, the data submitted to the board under subdivision 4 is private data on individuals as defined in section 13.02, subdivision 12, and not subject to public disclosure.\n\n(b) Except as specified in subdivision 5, the following persons shall be considered permissible users and may access the data submitted under subdivision 4 in the same or similar manner, and for the same or similar purposes, as those persons who are authorized to access similar private data on individuals under federal and state law:\n\n(1) a prescriber or an agent or employee of the prescriber to whom the prescriber has delegated the task of accessing the data, to the extent the information relates specifically to a current patient, to whom the prescriber is:\n\n(i) prescribing or considering prescribing any controlled substance;\n\n(ii) providing emergency medical treatment for which access to the data may be necessary;\n\n(iii) providing care, and the prescriber has reason to believe, based on clinically valid indications, that the patient is potentially abusing a controlled substance; or\n\n(iv) providing other medical treatment for which access to the data may be necessary for a clinically valid purpose and the patient has consented to access to the submitted data, and with the provision that the prescriber remains responsible for the use or misuse of data accessed by a delegated agent or employee;\n\n(2) a dispenser or an agent or employee of the dispenser to whom the dispenser has delegated the task of accessing the data, to the extent the information relates specifically to a current patient to whom that dispenser is dispensing or considering dispensing any controlled substance and with the provision that the dispenser remains responsible for the use or misuse of data accessed by a delegated agent or employee;\n\n(3) a licensed dispensing practitioner or licensed pharmacist to the extent necessary to determine whether corrections made to the data reported under subdivision 4 are accurate;\n\n(4) a licensed pharmacist who is providing pharmaceutical care for which access to the data may be necessary to the extent that the information relates specifically to a current patient for whom the pharmacist is providing pharmaceutical care: (i) if the patient has consented to access to the submitted data; or (ii) if the pharmacist is consulted by a prescriber who is requesting data in accordance with clause (1);\n\n(5) an individual who is the recipient of a controlled substance prescription for which data was submitted under subdivision 4, or a guardian of the individual, parent or guardian of a minor, or health care agent of the individual acting under a health care directive under chapter 145C. For purposes of this clause, access by individuals includes persons in the definition of an individual under section 13.02;\n\n(6) personnel or designees of a health-related licensing board listed in section 214.01, subdivision 2, or of the Emergency Medical Services Regulatory Board, assigned to conduct a bona fide investigation of a complaint received by that board that alleges that a specific licensee is impaired by use of a drug for which data is collected under subdivision 4, has engaged in activity that would constitute a crime as defined in section 152.025, or has engaged in the behavior specified in subdivision 5, paragraph (a);\n\n(7) personnel of the board engaged in the collection, review, and analysis of controlled substance prescription information as part of the assigned duties and responsibilities under this section;\n\n(8) authorized personnel under contract with the board, or under contract with the state of Minnesota and approved by the board, who are engaged in the design, evaluation, implementation, operation, or maintenance of the prescription monitoring program as part of the assigned duties and responsibilities of their employment, provided that access to data is limited to the minimum amount necessary to carry out such duties and responsibilities, and subject to the requirement of de-identification and time limit on retention of data specified in subdivision 5, paragraphs (d) and (e);\n\n(9) federal, state, and local law enforcement authorities acting pursuant to a valid search warrant;\n\n(10) personnel of the Minnesota health care programs assigned to use the data collected under this section to identify and manage recipients whose usage of controlled substances may warrant restriction to a single primary care provider, a single outpatient pharmacy, and a single hospital;\n\n(11) personnel of the Department of Human Services assigned to access the data pursuant to paragraph (k);\n\n(12) personnel of the health professionals services program established under section 214.31, to the extent that the information relates specifically to an individual who is currently enrolled in and being monitored by the program, and the individual consents to access to that information. The health professionals services program personnel shall not provide this data to a health-related licensing board or the Emergency Medical Services Regulatory Board, except as permitted under section 214.33, subdivision 3;\n\n(13) personnel or designees of a health-related licensing board other than the Board of Pharmacy listed in section 214.01, subdivision 2, assigned to conduct a bona fide investigation of a complaint received by that board that alleges that a specific licensee is inappropriately prescribing controlled substances as defined in this section. For the purposes of this clause, the health-related licensing board may also obtain utilization data; and\n\n(14) personnel of the board specifically assigned to conduct a bona fide investigation of a specific licensee or registrant. For the purposes of this clause, the board may also obtain utilization data.\n\n(c) By July 1, 2017, every prescriber licensed by a health-related licensing board listed in section 214.01, subdivision 2, practicing within this state who is authorized to prescribe controlled substances for humans and who holds a current registration issued by the federal Drug Enforcement Administration, and every pharmacist licensed by the board and practicing within the state, shall register and maintain a user account with the prescription monitoring program. Data submitted by a prescriber, pharmacist, or their delegate during the registration application process, other than their name, license number, and license type, is classified as private pursuant to section 13.02, subdivision 12.\n\n(d) Notwithstanding paragraph (b), beginning January 1, 2021, a prescriber or an agent or employee of the prescriber to whom the prescriber has delegated the task of accessing the data, must access the data submitted under subdivision 4 to the extent the information relates specifically to the patient:\n\n(1) before the prescriber issues an initial prescription order for a Schedules II through IV opiate controlled substance to the patient; and\n\n(2) at least once every three months for patients receiving an opiate for treatment of chronic pain or participating in medically assisted treatment for an opioid addiction.\n\n(e) Paragraph (d) does not apply if:\n\n(1) the patient is receiving palliative care, or hospice or other end-of-life care;\n\n(2) the patient is being treated for pain due to cancer or the treatment of cancer;\n\n(3) the prescription order is for a number of doses that is intended to last the patient five days or less and is not subject to a refill;\n\n(4) the prescriber and patient have a current or ongoing provider/patient relationship of a duration longer than one year;\n\n(5) the prescription order is issued within 14 days following surgery or three days following oral surgery or follows the prescribing protocols established under the opioid prescribing improvement program under section 256B.0638;\n\n(6) the controlled substance is prescribed or administered to a patient who is admitted to an inpatient hospital;\n\n(7) the controlled substance is lawfully administered by injection, ingestion, or any other means to the patient by the prescriber, a pharmacist, or by the patient at the direction of a prescriber and in the presence of the prescriber or pharmacist;\n\n(8) due to a medical emergency, it is not possible for the prescriber to review the data before the prescriber issues the prescription order for the patient; or\n\n(9) the prescriber is unable to access the data due to operational or other technological failure of the program so long as the prescriber reports the failure to the board.\n\n(f) Only permissible users identified in paragraph (b), clauses (1), (2), (3), (4), (7), (8), (10), and (11), may directly access the data electronically. No other permissible users may directly access the data electronically. If the data is directly accessed electronically, the permissible user shall implement and maintain a comprehensive information security program that contains administrative, technical, and physical safeguards that are appropriate to the user's size and complexity, and the sensitivity of the personal information obtained. The permissible user shall identify reasonably foreseeable internal and external risks to the security, confidentiality, and integrity of personal information that could result in the unauthorized disclosure, misuse, or other compromise of the information and assess the sufficiency of any safeguards in place to control the risks.\n\n(g) The board shall not release data submitted under subdivision 4 unless it is provided with evidence, satisfactory to the board, that the person requesting the information is entitled to receive the data.\n\n(h) The board shall maintain a log of all persons who access the data for a period of at least three years and shall ensure that any permissible user complies with paragraph (c) prior to attaining direct access to the data.\n\n(i) Section 13.05, subdivision 6, shall apply to any contract the board enters into pursuant to subdivision 2. A vendor shall not use data collected under this section for any purpose not specified in this section.\n\n(j) The board may participate in an interstate prescription monitoring program data exchange system provided that permissible users in other states have access to the data only as allowed under this section, and that section 13.05, subdivision 6, applies to any contract or memorandum of understanding that the board enters into under this paragraph.\n\n(k) With available appropriations, the commissioner of human services shall establish and implement a system through which the Department of Human Services shall routinely access the data for the purpose of determining whether any client enrolled in an opioid treatment program licensed according to chapter 245A has been prescribed or dispensed a controlled substance in addition to that administered or dispensed by the opioid treatment program. When the commissioner determines there have been multiple prescribers or multiple prescriptions of controlled substances, the commissioner shall:\n\n(1) inform the medical director of the opioid treatment program only that the commissioner determined the existence of multiple prescribers or multiple prescriptions of controlled substances; and\n\n(2) direct the medical director of the opioid treatment program to access the data directly, review the effect of the multiple prescribers or multiple prescriptions, and document the review.\n\nIf determined necessary, the commissioner of human services shall seek a federal waiver of, or exception to, any applicable provision of Code of Federal Regulations, title 42, section 2.34, paragraph (c), prior to implementing this paragraph.\n\n(l) The board shall review the data submitted under subdivision 4 on at least a quarterly basis and shall establish criteria, in consultation with the advisory task force, for referring information about a patient to prescribers and dispensers who prescribed or dispensed the prescriptions in question if the criteria are met.\n\n(m) The board shall conduct random audits, on at least a quarterly basis, of electronic access by permissible users, as identified in paragraph (b), clauses (1), (2), (3), (4), (7), (8), (10), and (11), to the data in subdivision 4, to ensure compliance with permissible use as defined in this section. A permissible user whose account has been selected for a random audit shall respond to an inquiry by the board, no later than 30 days after receipt of notice that an audit is being conducted. Failure to respond may result in deactivation of access to the electronic system and referral to the appropriate health licensing board, or the commissioner of human services, for further action. The board shall report the results of random audits to the chairs and ranking minority members of the legislative committees with jurisdiction over health and human services policy and finance and government data practices.\n\n(n) A permissible user who has delegated the task of accessing the data in subdivision 4 to an agent or employee shall audit the use of the electronic system by delegated agents or employees on at least a quarterly basis to ensure compliance with permissible use as defined in this section. When a delegated agent or employee has been identified as inappropriately accessing data, the permissible user must immediately remove access for that individual and notify the board within seven days. The board shall notify all permissible users associated with the delegated agent or employee of the alleged violation.\n\n(o) A permissible user who delegates access to the data submitted under subdivision 4 to an agent or employee shall terminate that individual's access to the data within three business days of the agent or employee leaving employment with the permissible user. The board may conduct random audits to determine compliance with this requirement.\n\n§\n\nSubdivision 1.Deferring prosecution for certain first time drug offenders.\n\n(a) A court may defer prosecution as provided in paragraph (c) for any person found guilty, after trial or upon a plea of guilty, of a violation of section 152.023, subdivision 2, 152.024, subdivision 2, 152.025, subdivision 2, or 152.027, subdivision 2, 3, 4, or 6, paragraph (d), for possession of a controlled substance, who:\n\n(1) has not previously participated in or completed a diversion program authorized under section 401.065;\n\n(2) has not previously been placed on probation without a judgment of guilty and thereafter been discharged from probation under this section; and\n\n(3) has not been convicted of a felony violation of this chapter, including a felony-level attempt or conspiracy, or been convicted by the United States or another state of a similar offense that would have been a felony under this chapter if committed in Minnesota, unless ten years have elapsed since discharge from sentence.\n\n(b) The court must defer prosecution as provided in paragraph (c) for any person found guilty of a violation of section 152.025, subdivision 2, who:\n\n(1) meets the criteria listed in paragraph (a), clauses (1) to (3); and\n\n(2) has not previously been convicted of a felony offense under any state or federal law or of a gross misdemeanor under section 152.025.\n\n(c) In granting relief under this section, the court shall, without entering a judgment of guilty and with the consent of the person, defer further proceedings and place the person on probation upon such reasonable conditions as it may require and for a period, not to exceed the maximum sentence provided for the violation. The court may give the person the opportunity to attend and participate in an appropriate program of education regarding the nature and effects of alcohol and drug abuse as a stipulation of probation. Upon violation of a condition of the probation, the court may enter an adjudication of guilt and proceed as otherwise provided. The court may, in its discretion, dismiss the proceedings against the person and discharge the person from probation before the expiration of the maximum period prescribed for the person's probation. If during the period of probation the person does not violate any of the conditions of the probation, then upon expiration of the period the court shall discharge the person and dismiss the proceedings against that person. Discharge and dismissal under this subdivision shall be without court adjudication of guilt, but a not public record of it shall be retained by the Bureau of Criminal Apprehension for the purpose of use by the courts in determining the merits of subsequent proceedings against the person. The not public record may also be opened only upon court order for purposes of a criminal investigation, prosecution, or sentencing. Upon receipt of notice that the proceedings were dismissed, the Bureau of Criminal Apprehension shall notify the arresting or citing law enforcement agency and direct that agency to seal its records related to the charge. Upon request by law enforcement, prosecution, or corrections authorities, the bureau shall notify the requesting party of the existence of the not public record and the right to seek a court order to open it pursuant to this section. The court shall forward a record of any discharge and dismissal under this subdivision to the bureau which shall make and maintain the not public record of it as provided under this subdivision. The discharge or dismissal shall not be deemed a conviction for purposes of disqualifications or disabilities imposed by law upon conviction of a crime or for any other purpose.\n\nFor purposes of this subdivision, \"not public\" has the meaning given in section 13.02, subdivision 8a.\n\n[See Note.]\n\n§\n\nSubdivision 1.Manufacturer; requirements.\n\n(a) A manufacturer may operate eight distribution facilities, which may include the manufacturer's single location for cultivation, harvesting, manufacturing, packaging, and processing but is not required to include that location. The commissioner shall designate the geographical service areas to be served by each manufacturer based on geographical need throughout the state to improve patient access. A manufacturer shall not have more than two distribution facilities in each geographical service area assigned to the manufacturer by the commissioner. A manufacturer shall operate only one location where all cultivation, harvesting, manufacturing, packaging, and processing of medical cannabis shall be conducted. This location may be one of the manufacturer's distribution facility sites. The additional distribution facilities may dispense medical cannabis and medical cannabis products but may not contain any medical cannabis in a form other than those forms allowed under section 152.22, subdivision 6, and the manufacturer shall not conduct any cultivation, harvesting, manufacturing, packaging, or processing at the other distribution facility sites. Any distribution facility operated by the manufacturer is subject to all of the requirements applying to the manufacturer under sections 152.22 to 152.37, including, but not limited to, security and distribution requirements.\n\n(b) A manufacturer may acquire hemp grown in this state from a hemp grower, and may acquire hemp products produced by a hemp processor. A manufacturer may manufacture or process hemp and hemp products into an allowable form of medical cannabis under section 152.22, subdivision 6. Hemp and hemp products acquired by a manufacturer under this paragraph are subject to the same quality control program, security and testing requirements, and other requirements that apply to medical cannabis under sections 152.22 to 152.37 and Minnesota Rules, chapter 4770.\n\n(c) A medical cannabis manufacturer shall contract with a laboratory approved by the commissioner, subject to any additional requirements set by the commissioner, for purposes of testing medical cannabis manufactured or hemp or hemp products acquired by the medical cannabis manufacturer as to content, contamination, and consistency to verify the medical cannabis meets the requirements of section 152.22, subdivision 6. The cost of laboratory testing shall be paid by the manufacturer.\n\n(d) The operating documents of a manufacturer must include:\n\n(1) procedures for the oversight of the manufacturer and procedures to ensure accurate record keeping;\n\n(2) procedures for the implementation of appropriate security measures to deter and prevent the theft of medical cannabis and unauthorized entrance into areas containing medical cannabis; and\n\n(3) procedures for the delivery and transportation of hemp between hemp growers and manufacturers and for the delivery and transportation of hemp products between hemp processors and manufacturers.\n\n(e) A manufacturer shall implement security requirements, including requirements for the delivery and transportation of hemp and hemp products, protection of each location by a fully operational security alarm system, facility access controls, perimeter intrusion detection systems, and a personnel identification system.\n\n(f) A manufacturer shall not share office space with, refer patients to a health care practitioner, or have any financial relationship with a health care practitioner.\n\n(g) A manufacturer shall not permit any person to consume medical cannabis on the property of the manufacturer.\n\n(h) A manufacturer is subject to reasonable inspection by the commissioner.\n\n(i) For purposes of sections 152.22 to 152.37, a medical cannabis manufacturer is not subject to the Board of Pharmacy licensure or regulatory requirements under chapter 151.\n\n(j) A medical cannabis manufacturer may not employ any person who is under 21 years of age or who has been convicted of a disqualifying felony offense. An employee of a medical cannabis manufacturer must submit a completed criminal history records check consent form, a full set of classifiable fingerprints, and the required fees for submission to the Bureau of Criminal Apprehension before an employee may begin working with the manufacturer. The bureau must conduct a Minnesota criminal history records check and the superintendent is authorized to exchange the fingerprints with the Federal Bureau of Investigation to obtain the applicant's national criminal history record information. The bureau shall return the results of the Minnesota and federal criminal history records checks to the commissioner.\n\n(k) A manufacturer may not operate in any location, whether for distribution or cultivation, harvesting, manufacturing, packaging, or processing, within 1,000 feet of a public or private school existing before the date of the manufacturer's registration with the commissioner.\n\n(l) A manufacturer shall comply with reasonable restrictions set by the commissioner relating to signage, marketing, display, and advertising of medical cannabis.\n\n(m) Before a manufacturer acquires hemp from a hemp grower or hemp products from a hemp processor, the manufacturer must verify that the hemp grower or hemp processor has a valid license issued by the commissioner of agriculture under chapter 18K.\n\n(n) Until a state-centralized, seed-to-sale system is implemented that can track a specific medical cannabis plant from cultivation through testing and point of sale, the commissioner shall conduct at least one unannounced inspection per year of each manufacturer that includes inspection of:\n\n(1) business operations;\n\n(2) physical locations of the manufacturer's manufacturing facility and distribution facilities;\n\n(3) financial information and inventory documentation, including laboratory testing results; and\n\n(4) physical and electronic security alarm systems.\n\n[See Note.]\n\n§\n\nSubd. 2.Criminal and civil protections.\n\n(a) Subject to section 152.23, the following are not violations under this chapter:\n\n(1) use or possession of medical cannabis or medical cannabis products by a patient enrolled in the registry program; possession by a registered designated caregiver or the parent, legal guardian, or spouse of a patient if the parent, legal guardian, or spouse is listed on the registry verification; or use or possession of medical cannabis or medical cannabis products by a Tribal medical cannabis program patient;\n\n(2) possession, dosage determination, or sale of medical cannabis or medical cannabis products by a medical cannabis manufacturer, employees of a manufacturer, a Tribal medical cannabis program manufacturer, employees of a Tribal medical cannabis program manufacturer, a laboratory conducting testing on medical cannabis, or employees of the laboratory; and\n\n(3) possession of medical cannabis or medical cannabis products by any person while carrying out the duties required under sections 152.22 to 152.37.\n\n(b) Medical cannabis obtained and distributed pursuant to sections 152.22 to 152.37 and associated property is not subject to forfeiture under sections 609.531 to 609.5316.\n\n(c) The commissioner, members of a Tribal medical cannabis board, the commissioner's or Tribal medical cannabis board's staff, the commissioner's or Tribal medical cannabis board's agents or contractors, and any health care practitioner are not subject to any civil or disciplinary penalties by the Board of Medical Practice, the Board of Nursing, or by any business, occupational, or professional licensing board or entity, solely for participation in the registry program under sections 152.22 to 152.37 or in a Tribal medical cannabis program. A pharmacist licensed under chapter 151 is not subject to any civil or disciplinary penalties by the Board of Pharmacy when acting in accordance with the provisions of sections 152.22 to 152.37. Nothing in this section affects a professional licensing board from taking action in response to violations of any other section of law.\n\n(d) Notwithstanding any law to the contrary, the commissioner, the governor of Minnesota, or an employee of any state agency may not be held civilly or criminally liable for any injury, loss of property, personal injury, or death caused by any act or omission while acting within the scope of office or employment under sections 152.22 to 152.37.\n\n(e) Federal, state, and local law enforcement authorities are prohibited from accessing the patient registry under sections 152.22 to 152.37 except when acting pursuant to a valid search warrant.\n\n(f) Notwithstanding any law to the contrary, neither the commissioner nor a public employee may release data or information about an individual contained in any report, document, or registry created under sections 152.22 to 152.37 or any information obtained about a patient participating in the program, except as provided in sections 152.22 to 152.37.\n\n(g) No information contained in a report, document, or registry or obtained from a patient under sections 152.22 to 152.37 or from a Tribal medical cannabis program patient may be admitted as evidence in a criminal proceeding unless independently obtained or in connection with a proceeding involving a violation of sections 152.22 to 152.37.\n\n(h) Notwithstanding section 13.09, any person who violates paragraph (e) or (f) is guilty of a gross misdemeanor.\n\n(i) An attorney may not be subject to disciplinary action by the Minnesota Supreme Court, a Tribal court, or the professional responsibility board for providing legal assistance to prospective or registered manufacturers or others related to activity that is no longer subject to criminal penalties under state law pursuant to sections 152.22 to 152.37, or for providing legal assistance to a Tribal medical cannabis program or a Tribal medical cannabis program manufacturer.\n\n(j) The following do not constitute probable cause or reasonable suspicion, and shall not be used to support a search of the person or property of the person possessing or applying for the registry verification or equivalent, or otherwise subject the person or property of the person to inspection by any governmental agency:\n\n(1) possession of a registry verification or application for enrollment in the registry program by a person entitled to possess a registry verification or apply for enrollment in the registry program; or\n\n(2) possession of a verification or equivalent issued by a Tribal medical cannabis program or application for enrollment in a Tribal medical cannabis program by a person entitled to possess such a verification or application."
    }
}